The Current State of Management of Locally Advanced/Metastatic Urothelial Carcinoma
Expert perspectives on the current treatment paradigm for patients diagnosed with locally advanced or metastatic urothelial carcinoma.
Clinical Pearls for Community Oncologists Treating RCC
Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.
COSMIC-313 and Role of Triplet Regimens in Frontline Setting in Advanced RCC
A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.
Managing Immune-Related Adverse Events in RCC
Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.
Managing TKI-Related Adverse Events in RCC
An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.
IO-IO Regimens in Advanced RCC: Recent Data Updates
Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.
Role of Radiation in the Treatment of RCC
Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.
Patient Profile 2: A 59-Year-Old Woman with Advanced Renal Cell Carcinoma
A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.
Treatment Options in Advanced RCC in the Second-Line Setting
RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.
IO-TKI Regimens in Advanced RCC: Does the Choice of TKI Matter?
Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.
Selecting the Optimal Treatment Regimen for Favorable-Risk RCC
Experts on renal cell carcinoma discuss frontline treatment options for favorable-risk disease and factors that impact treatment decisions.
Selecting the Appropriate IO-TKI in Frontline Setting in Advanced RCC
A comprehensive discussion on how to select the appropriate IO-TKI regimen in the frontline setting in advanced renal cell carcinoma.
IO-TKI Regimens in Advanced RCC: Recent Data Updates
A panel of experts on renal cell carcinoma review updated data on IO-TKI regimens in advanced RCC, including the CheckMate 9ER, KEYNOTE-526, and CLEAR trials.
Molecular Testing and Risk Stratification in Advanced Clear Cell RCC
Expert oncologists give an overview of molecular testing, risk stratification, and treatment guidelines for renal cell carcinoma.
Overview of Renal Cell Carcinoma and Case of a 61-Year-Old Man with Metastatic Clear Cell RCC
A panel of expert genitourinary oncologists give an overview of renal cell carcinoma and present the case of a 61-year-old man with metastatic clear cell RCC.
Favorable Efficacy and Tolerability for Lenvatinib/Pembrolizumab in RCC
Pedro C. Barata, MD, MSc, explains how the favorable efficacy and tolerability of lenvatinib and pembrolizumab observed in the CLEAR trial helps provide a standard of care in this patient population.
Questions Around Precision Medicine for Prostate Cancer
Pedro C. Barata, MD, MSc, discusses research topics to help bring more precision medicine options to the prostate cancer landscape.
Hitting New Targets in Metastatic Prostate Cancer
In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.
Recommendations for Treating Non–Clear Cell RCC
Pedro C. Barata, MD, MSc, discusses treatment options for patients with non–clear cell renal cell carcinoma.
2 Clarke Drive Cranbury, NJ 08512